![John Lowe](https://ddf.vc/wp-content/uploads/2023/10/john-lowe.jpg)
John Lowe
Medchem Advisor
John A. Lowe III is a medicinal chemist with 30 years of experience in drug discovery and development at Pfizer, Inc. He co-discovered the first nonpeptide Substance P (NK1) receptor antagonist, and the novel, atypical antipsychotic drug, ziprasidone. Since 2009, he consults for the biotech and pharmaceutical industry on drug design and conducts third-party due diligence evaluation.